Julie Gosper, Managing Director, Rare & Specialty at Sciensus, where she leads the strategy, commercial execution and operational delivery of the company’s fastest-growing business segment. She is responsible for advancing Sciensus’ integrated rare disease offering, which spans early access programmes, licensing, distribution, in-home clinical care and in-market patient support, helping global biotechs design, launch and scale rare and ultra-rare disease products across Europe.
As a trusted operational partner to biotech companies , Julie focuses on widening Sciensus’ pipeline of partnerships, particularly with biotechs preparing for their first European launches. She leverages the company’s proven model that combines distribution, patient support and real-world evidence to deliver the right medicine to the right patient, faster, accelerating access to life-changing therapies for underserved patient populations.
With 20 years of global experience, she brings deep expertise in shaping commercial pathways, unlocking market entry in demanding markets and guiding therapies from early access to full launch across Europe’s complex healthcare landscape.
Julie joins Sciensus from Clinigen, where she served as Senior Vice President for Europe, the US and rest of world with responsibility for commercial strategy, market expansion and product partnerships. Earlier roles include leadership positions in health economics, portfolio strategy, unlicensed medicines and global partnering across multiple markets. Her career has been built around enabling availability of specialised and often hard-to-reach medicines, with particular focus on underserved patient populations.
Trained as a clinical pharmacist, Julie combines frontline clinical insight with hands-on commercial leadership developed across Europe, the US and Asia Pacific.